Renalytix AI plc (RENX)

860.00
-4.00(-0.45%)
  • Volume:
    4,235
  • Bid/Ask:
    860.00/900.00
  • Day's Range:
    860.00 - 860.00

RENX Overview

Prev. Close
884
Day's Range
860-860
Revenue
290.84K
Open
905
52 wk Range
430-1,220
EPS
-0.19
Volume
4,235
Market Cap
638.61M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
60,776
P/E Ratio
-
Beta
-
1-Year Change
98.65%
Shares Outstanding
72,240,706
Next Earnings Date
01 Dec 2021
What is your sentiment on Renalytix AI plc?
or
Vote to see community's results!

Renalytix AI plc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellNeutralBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong BuyStrong Buy
SummaryStrong SellStrong SellStrong SellBuyStrong Buy

Renalytix AI plc Company Profile

Renalytix AI plc Company Profile

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.